2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1346237583 M.D.
Verify on CMS →

BARRY IZENSTEIN, M.D.

Endocrinology, Diabetes & Metabolism Physician in SPRINGFIELD, Massachusetts. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
8K
Medicare Part D claims · 657 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
76%
generic claims · 24% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
79.7715/100
▼ 3 pts below national avg 83.1 · [object Object]
Industry payments
$681.11
32 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

BARRY IZENSTEIN, M.D. reported a CMS MIPS final score of 79.7715/100 — below the 83.1 national average — and filed 8,172 Medicare Part D claims in 2023.

79.7715/100
MIPS score · -3 vs avg
8K
Part D claims, 2023
76%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

BARRY IZENSTEIN, M.D.'s MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

80 30th percentile higher than 30% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). This entry sits in this band. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

BARRY IZENSTEIN, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about BARRY IZENSTEIN, M.D.?

Near national average

NPI registry status

Active

Issued 10/03/2005

NPI 1346237583

Primary specialty

Endocrinology, Diabetes & Metabolism Physician

Mid-sized

7,852 US NPIs in this specialty

Medicare Part D claims

8,172 210% vs specialty avg

2023 prescription claims

Specialty avg: 2,639

MIPS final score

79.7715/100 3.328499999999991% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Massachusetts

How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Massachusetts providers

Massachusetts providers

Endocrinology, Diabetes & Metabolism Physician share within Massachusetts

1. Endocrinology, Diabetes & Metabolism Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Endocrinology, Diabetes & Metabolism Physician share within Massachusetts

Medicare quality performance — MIPS

BARRY IZENSTEIN, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average

Near national average
MIPS Final Score
79.7715/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 79.7715/100 vs national avg 83.1

0%100%National avg83%79.8%
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 79.7715/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

BARRY IZENSTEIN, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 2 MEDICAL CENTER DR, SPRINGFIELD, MA, 01107, with a listed phone of (413) 734-4667. NPI 1346237583 was issued on 10/03/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what IZENSTEIN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 8,172 prescription claims written by this provider, covering 657 Medicare beneficiaries and totaling roughly $2.2 million in drug spend, split 24% brand-name and 76% generic by claim count, with an opioid prescribing rate of 1.1%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 79.7715/100 for the 2023 performance year (Quality 82.1497, Cost 56.372), compared with the national average of 83.1.

Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

2 MEDICAL CENTER DR
SPRINGFIELD, MA 01107

Provider Details

NPI 1346237583
Specialty Endocrinology, Diabetes & Metabolism Physician
Credentials M.D.
Gender Male
NPI Issued 10/03/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

79.7715
Final Score
Avg: 83.1
82.1497
Quality
56.372
Cost

Reporting: Group practice

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for BARRY IZENSTEIN, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$681

Largest payer

Lilly USA, LLC

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Massachusetts BORIM 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~38K Massachusetts medical licensees in 2023 — they are NOT specific to BARRY IZENSTEIN, M.D.. To verify BARRY IZENSTEIN, M.D.'s current license status, search the BORIM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

80
Total board actions, Massachusetts 2023
Across 78 cases
2.11
Actions per 1,000 licensees
Massachusetts statewide rate
probation
Most common action type
29 cases

BORIM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Massachusetts disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

BARRY IZENSTEIN, M.D. — brand share 24.0%
Specialty average (est.)

24% brand-name claims vs 76% generic, on 8,172 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

8,172
Total Claims
$2.2M
Total Drug Cost
657
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
18,798
Total Day Supply
554,340
Brand vs Generic
24% brand / 76% generic
Brand Drug Cost
$2.1M
Generic Drug Cost
$113K
Opioid Claims
91 (1.1% rate)
Antibiotic Claims
70

Patient Demographics

Average Patient Age
75.9 years
Avg HCC Risk Score
1.16
Gender Split
48% female / 52% male
Age Distribution
<65: 36, 65-74: 264, 75-84: 249, 85+: 108

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What BARRY IZENSTEIN, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Trulicity
Dulaglutide
440
Amlodipine Besylate
434
Levothyroxine Sodium
429
Hydrochlorothiazide
316
Losartan Potassium
313
Atorvastatin Calcium
310
Lisinopril
283
Metformin Hcl
239
Simvastatin
220
Metoprolol Succinate
204

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Endocrinology, Diabetes & Metabolism Physician Overview

How BARRY IZENSTEIN, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.

7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider

BARRY IZENSTEIN, M.D.'s 8,172 claims are above the specialty average of 2,639.

Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Massachusetts

Other clinicians with the same primary specialty enrolled in Massachusetts, drawn from the same CMS NPPES roster as IZENSTEIN.

Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is BARRY IZENSTEIN, M.D.'s specialty?
BARRY IZENSTEIN, M.D. specializes in Endocrinology, Diabetes & Metabolism Physician and practices in SPRINGFIELD, Massachusetts. Credentials: M.D..
How much does BARRY IZENSTEIN, M.D. prescribe under Medicare Part D?
In 2023, BARRY IZENSTEIN, M.D. wrote 8,172 Medicare Part D claims totaling $2.2M in drug costs for 657 beneficiaries.
What is BARRY IZENSTEIN, M.D.'s Medicare quality score?
BARRY IZENSTEIN, M.D. has a CMS MIPS Final Score of 79.7715/100 (Quality: 82.1497, Cost: 56.372). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is BARRY IZENSTEIN, M.D. located?
BARRY IZENSTEIN, M.D. is located at 2 MEDICAL CENTER DR, SPRINGFIELD, MA, 01107. Phone: (413) 734-4667.
What is BARRY IZENSTEIN, M.D.'s NPI number?
BARRY IZENSTEIN, M.D.'s National Provider Identifier (NPI) is 1346237583, issued on 10/03/2005.
Does BARRY IZENSTEIN, M.D. prescribe more brand-name or generic drugs?
BARRY IZENSTEIN, M.D.'s prescribing is 24% brand-name and 76% generic drugs by claim count, with $2.1M in brand drug costs.
Does BARRY IZENSTEIN, M.D. prescribe opioids?
Yes, BARRY IZENSTEIN, M.D. had 91 opioid claims in 2023 with an opioid prescribing rate of 1.1%.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US?
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does BARRY IZENSTEIN, M.D. prescribe most often?
Based on 2023 Medicare Part D data, BARRY IZENSTEIN, M.D.'s most frequently prescribed drugs include Trulicity, Amlodipine Besylate, Levothyroxine Sodium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does BARRY IZENSTEIN, M.D. accept Medicare?
BARRY IZENSTEIN, M.D. appears in CMS Medicare data with 8,172 Part D claims and 657 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify BARRY IZENSTEIN, M.D.'s credentials?
BARRY IZENSTEIN, M.D.'s NPI is 1346237583 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology